Management of
Steroid Refractory Graft
versus Host Disease
At the recent 27th Annual Scientific Meeting of the Malaysian Society of Transplantations, Dr Jason Butler, Clinical Haematologist, Icon Care Centre Brisbane and Icon Cancer Centre Chermside, discussed the complex topic of graft versus host disease (GvHD). In particular, the talk centred on the topic of steroid-refractory graft-versus-host disease (SR-GvHD), with a particular focus on the recent advancements using ruxolitinib and the significant benefits ruxolitinib offers compared to the best available therapies (BAT).
